Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease

Bone Marrow Transplantation

Volumn 23, Issue 8, 1999, Pages 839-842

  Perry, J J ^a   Fleming, R A ^a   Rocco, M V ^a   Petros, W P ^b   Bleyer, A J ^a   Radford Jr , J E ^a   Powell, B L ^a   Hurd, D D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Allogeneic BMT; AML; Cyclophosphamide; Hemodialysis; Pharmacokinetics; Renal disease

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ACUTE LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; CHRONIC KIDNEY FAILURE; CONDITIONING; CYTOGENETICS; DRUG ELIMINATION; DRUG MEGADOSE; HEMODIALYSIS; HUMAN; KARYOTYPE; LEUKOCYTE; MALE; PRIORITY JOURNAL; REMISSION; THROMBOCYTE; WHOLE BODY RADIATION;

EID: 0032951656     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701646     Document Type: Article

References (20)

1. Chen TL, Kennedy MJ, Anderson LW et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Disp 1997; 25: 544-551.
2. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981; 19: 443-451.
3. Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 1975; 36: 409-414.
4. Humphrey RL, Kvols LK. The influence of renal insufficiency on cyclophosphamide induced hematopoietic depression and recovery. Proc Am Assoc Cancer Res 1974; 15: 84 (Abstr.).
5. Tew KD, Colvin M, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy. Lippincott-Raven: Philadelphia, 1996, pp 297-332.
6. Powell BL, Lyerly ES, Cottrell DL et al. Successful induction chemotherapy for acute myeloid leukemia in a patient with hemodialysis-dependent chronic renal failure. Blood 1995; 86: 775a (Abstr.).
7. Moore MJ, Hardy RW, Thiessen JJ et al. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988; 44: 622-628.
8. Gilbert CJ, Petros WP, Vrendenburgh J et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for the treatment of breast cancer. Cancer Chemother Pharmacol 1998; 42: 497-503.
9. Christian RA, Chaffee SK, Hovick CJ, Steele WJ. A stable colorimetric assay for cyclophosphamide and its alkylating metabolites based on the alkylation of 4-(4́-nitrobenzyl)-pyridine. Life Sci 1980; 27: 2595-2599.
10. Ninane J, Baurain R, de Kraker J et al. Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children. Cancer Chemother Pharmacol 1989; 24: (Suppl.): S2-S6.
11. D'Argenio DZ, Schumitzky AA. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 1979; 9: 115-134.
12. Wang LH, Lee CS, Majeske BL, Marbury TC. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cell, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 1981; 29: 365-372.
13. Ballester OF, Tummala R, Janssen WE et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653-656.
14. Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
15. Chen TL, Passos-Coelho JL, Noe DA et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 55: 810-816.
16. Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996; 14: 1484-1494.
17. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin 1991; 20: 194-208.
18. Wagner VT, Heydrich D, Bartels H, Hohorst HJ. Einflub von leberparenchymschaden, niereninsuffizienz und hamodialyse auf die pharmakokinetik von cyclophosphamid und seinen aktivierten metaboliten. Arzneim Forsch 1980; 30: 1588-1592.
19. Lewis LD. Ifosfamide pharmacokinetics. Invest New Drugs 1991; 9: 305-311.
20. Phillipou G, Seaborn CJ, Raniolo E. Reproducibility of methods relating to cyclophosphamide metabolic studies (letter). J Natl Cancer Inst 1993; 85: 1249-1250.